



Evaluation Report for Category B, Subcategory 3.11 Application

Application Number: 2019-5964
Application: New or Changes to Product Labels-New Pest
Product: Miravis Prime Fungicide
Registration Number: 33207
Active ingredients (a.i.): Pydiflumetofen (FMF), Fludioxonil (FLD)
PMRA Document Number: 3087215

Background

Miravis Prime Fungicide is a broad spectrum, preventative fungicide that contains the active ingredients pydiflumetofen and fludioxonil. It is registered in Canada to control several fungal diseases on multiple crops, including grape, at rates between 0.8-1.0 L/ha. On grape, it is labelled to control botrytis grey mould when applied at a rate of 0.8-1.0 L/ha and a 21 day interval, twice from early bloom until pre-harvest. For specific details of uses, application rates and methods, precautions, restrictions, and personal protective equipment requirements, refer to the product label.

Purpose of Application

The purpose of this application was to add a claim for the control powdery mildew on grape at a rate of 0.8-1.0 L/ha and a 21 day interval to the Miravis Prime Fungicide label. It is to be applied twice from early bloom until pre-harvest. Treatments of Miravis Prime Fungicide against powdery mildew are to be applied at the same time as those used to treat botrytis grey mould.

Chemistry Assessment

A chemistry assessment was not required as there was no change to the product formulation.

Health and Environmental Assessments

Health and environmental assessments were not required as there was no change to the use pattern, including host crops, application methods, timings and rates.

Value Assessment

To support the claim to control powdery mildew (*Erysiphe* syn. *Uncinula necator*) on grape by Miravis Prime Fungicide, the results of three suitable US grape efficacy trials were submitted. The results of an additional four European grape trials were provided as supplemental support. Powdery mildew on grape was controlled and the marketable yield of grapes was significantly increased when Miravis Prime Fungicide was applied according to the label directions registered for botrytis grey mould.

Powdery mildew can substantially decrease marketable grape yields. It commonly occurs with another important pathogen, botrytis grey mould. Adding the claim of powdery mildew control will allow the simultaneous control of both pathogens. This will increase the efficiency of grape disease management and may reduce the total amount of pesticides applied against these pathogens.

Conclusion

The PMRA has completed an assessment of the subject application and has concluded that the submitted value information is adequate to support a claim of control of powdery mildew on grape for Miravis Prime Fungicide when applied preventatively at a rate of 0.8-1.0 L/ha and a 21 day interval, twice from early bloom until pre-harvest.

References

PMRA #	Reference
3036119	2019, Value Summary, DACO: 10.1, 10.3.1, 10.3.2
3036120	2019, A20560 Data Summary, DACO: 10.2.3.1
3036121	"2018, A20560E -A19649H: trials in grapes against Powdery Mildew at Botrytis rate in EU28- 2018, DACO: 10.2.3.3"
3036122	"2018, A20560E -A19649H: trials in grapes against Powdery Mildew at Botrytis rate in EU28- 2018, DACO: 10.2.3.3"
3036123	"2018, A20560E -A19649H: trials in grapes against Powdery Mildew at Botrytis rate in EU28- 2018, DACO: 10.2.3.3"
3036124	"2018, A20560E -A19649H: trials in grapes against Powdery Mildew at Botrytis rate in EU28- 2018, DACO: 10.2.3.3"
3075034	2020, Value Summary, DACO: 10.1
3075035	2015, Evaluate A19649B and A20259E fungicides for powdery mildew control in grape, DACO: 10.2.3.3
3075036	2017, Evaluate Miravis Prime for powdery mildew control in grapes, DACO: 10.2.3.3
3075037	"2018, 2018 Miravis Prime: Evaluation for control of Botrytis/ PM on grape, DACO: 10.2.3.3"
3075038	2017, Evaluate Miravis Prime for powdery mildew control in grapes, DACO: 10.2.3.3
3075039	2018, 2019 APN+FLD Grapes for control of sour rot complex, DACO: 10.2.3.3

ISSN: 1911-8082

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health Canada, 2020

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.